Vetoquinol Acquires the Rights for Profender® from Elanco Animal Health for Canada
08 Februar 2021 - 06:00PM
Business Wire
Regulatory News:
Vetoquinol (Paris:VETO) announced today the acquisition of the
Canadian rights to Profender® product family from Elanco Animal
Health.
Vetoquinol has acquired the Profender® product family, the
intellectual property, registrations and other rights from Elanco
Animal Health for the Canadian market. This acquisition has been
approved by the Canadian Competion Bureau. The Profender® range
consists in spot-on de-wormer products for cats.
In August 2020, Vetoquinol acquired the Profender® and Drontal®
product families in the EU and the UK in relation to Elanco’s 2020
acquisition of Bayer AG’s animal health business. In January 2021,
Vetoquinol also acquired the Profender® and Drontal® product
families in Australia.
Matthieu Frechin, CEO of Vetoquinol, said: "We are very pleased
to acquire Profender® for the Canadian market, one of our prominent
strategic countries. The acquisition of this strong brand for the
Canadian market confirms our ambition to become a major player in
the parasiticide segment. Adding this Essential to our product
portfolio in Canada will strengthen our market share in the pet
segment in this strategic country.”
Next update: 2020 Annual results – April 1st 2021 before
Market opening
ABOUT VETOQUINOL Vetoquinol is a leading global animal health
company that supplies drugs and non-medicinal products for the
livestock (cattle and pigs) and pet (dogs and cats) markets. As an
independent pure player, Vetoquinol designs, develops and sells
veterinary drugs and non-medicinal products in Europe, the Americas
and the Asia Pacific region. Since its foundation in 1933,
Vetoquinol has been pursuing a strategy combining innovation with
geographical diversification. The Group's hybrid growth is driven
by the reinforcement of its product portfolio coupled with
acquisitions in high potential growth markets. At December 31st
2020, Vetoquinol employs 2,409 people. Vetoquinol has been listed
on Euronext Paris since 2006 (symbol: VETO).
www.vetoquinol.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210208005043/en/
VETOQUINOL
Investor Relations Fanny Toillon Tel.: +33 (0)3 84
62 59 88 relations.investisseurs@vetoquinol.com
KEIMA COMMUNICATION
Investor & Media Relations Emmanuel Dovergne
Tel.: +33 (0) 1 56 43 44 63 emmanuel.dovergne@keima.fr
Vetoquinol (EU:VETO)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Vetoquinol (EU:VETO)
Historical Stock Chart
Von Mär 2023 bis Mär 2024